MAPS Congratulates Lykos Therapeutics on Acceptance of New
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD....
Source: globenewswire.com
Page 32 - Priority Review News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Priority Review Today - Breaking & Trending Today
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
BOSTON & LONDON, Feb. 09, 2024 -- Centessa Pharmaceuticals plc announced that data from an additional 52-weeks of continuous treatment from the third year of the ongoing Phase 2a study of...
Source: marketscreener.com
Why Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday? - Humacyte (NASDAQ:HUMA)
Humacyte's shares surge as FDA grants Priority Review to its BLA for Human Acellular Vessel (HAV) used in urgent arterial repair.
Source: benzinga.com
Why Is Clinical-Stage Biotechnology Platform Company Humacyte Stock Gaining Friday?
Humacyte, Inc. HUMA shares are trading higher on Friday. The company announced that the U.S. FDA has accepted and granted Priority Review to Humacyte’s…
Source: biztoc.com
AstraZeneca Full year and Q4 2023 Financial Results
Strong growth and pipeline momentum with three new medicines approved since the third quarter ...
Source: marketscreener.com